Peptides are short chains of amino acids and play vital roles in cell signalling, hormonal regulation, and immune responses. Typically comprising of less than 50 amino acids, they bridge the gap between small molecules and large proteins. Because of their importance in human biology, they are increasingly being used as therapeutics in the treatment of chronic diseases.
InnoCore’s SynBiosys® platform is expertly engineered for extended release of structurally intact peptides and other APIs over weeks to months. By leveraging our proprietary polymeric drug delivery system, SynBiosys®, we protect delicate peptides from physiological degradation and develop new LAI drug products with important features. This includes, tunable release kinetics, absence of acidic polymer degradation products, low burst and structurally intact release of peptides for improved therapeutic outcomes.
The SynBiosys® polymer-based long-acting biodegradable drug delivery platform provides significant competitive advantages for our partners. We can overcome the technical challenges commonly associated with this class of molecule and deliver LAI peptide formulations with tunable release characteristics.
Examples of peptides
Peptides are biologically active oligomers—molecules composed of amino acid sequences typically shorter than proteins. Their inherent specificity and potency make them powerful therapeutic candidates across numerous clinical areas, including endocrinology, immunology, and oncology. However, their structural fragility and susceptibility to enzymatic breakdown often limit their clinical utility when formulated, making manufacturing, scalability and administration challenging.
InnoCore’s SynBiosys® drug delivery platform provides a sophisticated solution to these challenges. It is a biodegradable polymer matrix capable of encapsulating peptides, as well as larger proteins and small molecules, in various dosage forms such as microspheres, implants or in-situ forming depots. Upon exposure to an aqueous environment, the polymer swells and gradually releases the peptide via diffusion, delivering a controlled, linear release tailored from several days up to several months.
SynBiosys® offers essential protection across all stages of drug formulation and administration. Its matrix safeguards peptides from aggregation, enzymatic degradation, and acylation. This protective matrix protects peptides’ structural integrity and preserves biological activity. SynBiosys® is particularly well suited for sensitive peptide therapeutics that demand stability and efficacy.
One of SynBiosys®’s most powerful features is its tunability. By adjusting the composition and ratio of the blocks of the SynBiosys® polymeric matrix, the release duration can be finetuned from weeks to months, minimize burst effects, and adapt dosage profiles to match clinical demands.
InnoCore doesn’t stop at formulation development. We support our clients the entire development journey, from small scale formulation development feasibility studies to scale up and manufacturing of GLP-tox material, analytical characterization, and technology transfer. Our multidisciplinary team and state-of-the-art R&D facilities enable seamless translation of peptide-based formulations into robust, long-acting LAI products.
Peptide-based therapies offer tremendous potential but require precise delivery strategies to fully harness their benefits. InnoCore’s SynBiosys® drug delivery platform stands at the forefront of this translation, providing a science-backed, flexible, and scalable solution that protects fragile active ingredients while enabling customizable, long-lasting release. Trust our expertise to bring your peptide programs from concept to clinic with confidence.
"*" indicates required fields